WebDec 14, 2016 · The Diaceutics report includes a comprehensive review and update of 23 pharmaceutical and biotechnology companies with at least one diagnostically-enabled therapy on the market or significant pipeline investment in biomarkers, and ranks them according to their potential to capitalize on opportunities in diagnostic test-driven markets. WebMar 29, 2024 · Company Diaceutics PLC is a diagnostic commercialization company. The principal activity of the Company is data analytics and implementation services. The Company is engaged in research and development activities in drug development science, testing data and software platform development.
Annual Report & Statements - Diaceutics Plc (DXRX)
WebThe Diaceutics report follows comments made by John Castellani, ... At ASCO's annual meeting, Pfizer presented interim progression-free survival data for patients with ALK-positive advanced non-small cell lung cancer treated with an investigational ALK inhibitor, called crizotinib. The ongoing, open-label, multi-center, Phase I trial of 116 ... WebNov 10, 2024 · The latest research is part of Diaceutics' ongoing effortsto understand and quantify how access disparities in precision oncology are impacting patients. For example, in 2024, Diaceutics reported that … openbsd wayland
DIACEUTICS PLC : DXRX Stock Price GB00BJQTGV64
WebAvailable now the latest Precision Medicine Readiness Report. In this third, and final report of the Axis for Change series, we take a more forward-thinking approach that celebrates the ongoing, disruptive achievements … WebDiaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading … More pharmaceutical companies. They have built … WebMar 15, 2024 · 15 March, 2024. Diaceutics PLC (AIM: DXRX), a diagnostic commercialisation company for precision testing, reports its audited results for the year … open bsn account online